China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its investigational drug HDM1005. This long-acting agonist targets the GLP-1 receptor and GIP receptor and is under development for weight management in overweight or obese populations.
Pre-clinical studies have demonstrated that the Category 1 chemical drug can activate GLP-1 and GIP receptors, promote insulin release, suppress appetite, and significantly improve glucose tolerance, reduce blood sugar levels, and aid in weight loss. Existing data indicates that HDM1005 possesses favorable pharmacological properties and safety. The drug, which was approved for clinical trials in China last month, has already begun dosing healthy subjects in Phase Ia trials.- Flcube.com
